An Open-Label, Multicenter, Phase 1b/2 Study of RP1 in Solid Organ and Hematopoietic Cell Transplant Recipients with Advanced Cutaneous Malignancies
Contact:
NCT Number:
Protocol:
AAAV3907
Study Status:
Active/Enrolling
Population:
Adult
Phase:
I/II
This study is being done to find out how effective RP1 is in treating the cancer and how safe it is. These effects could be good (for example, shrinking of tumors) or bad (called side effects). Researchers will study the effects and how long they last. This study is being done to find out how effective RP1 is in treating the cancer and how safe it is.
Are you Eligible? (Inclusion Criteria)
- Are you 18 or older? - Have either kidney, liver, heart, or lung transplant - No history of lung disease
Specialty Area(s)
Melanoma, Immunotherapy
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
